Immunology - Immunotherapy

(P 122) AN UPDATE ON TNT: A PHASE-2 STUDY OF THE EFFICACY AND SAFETY OF TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN IN ADVANCED SARCOMA

(P 123) COMPLETE RESPONSES WITH SAINT PROTOCOL: A PHASE 2 STUDY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB, AND TRABECTEDIN IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (NCT03138161)

(P 124) EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA

(P 125) EFFECTIVENESS OF PERIPHERAL BLOOD IMMUNE-RELATED MARKERS IN SELECTING NOVEL THERAPEUTIC AGENTS FOR ADVANCED SOFT TISSUE SARCOMA

(P 126) GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN, NIVOLUMAB, AND DOCETAXEL AS SECOND/THIRD-LINE THERAPY FOR ADVANCED SARCOMA (NCT04535713)

(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS

(P 128) INVESTIGATING THE ROLE OF MACROPHAGES IN A MURINE MODEL OF SOFT TISSUE SARCOMA

(P 130) MONITORING SOFT TISSUE SARCOMA RESPONSE TO IMMUNE CHECKPOINT INHIBITION AND CRYOTHERAPY WITH CIRCULATING TUMOR DNA ANALYSIS

(P 131) MUCIN 16 (CANCER ANTIGEN 125) EXPRESSION IN EPITHELIOID SARCOMA LEADS TO SINGLE-PATIENT STUDY WITH BISPECIFIC T-CELL ENGAGER UBAMATAMAB (MUCIN16-CD3): A BENCH-TO-BEDSIDE EXPERIENCE

(P 132) PHASE 1/2 COMBINATION REGIMEN WITH IPILIMUMAB (I), NIVOLUMAB (N), AND TRABECTEDIN (T) AS FIRST-LINE THERAPY FOR ADVANCED LEIOMYOSARCOMA [NCT03138161]

(P 133) PHASE 2 COMBINATION REGIMEN WITH TALIMOGENE LAHERPAREPVEC (TVEC), NIVOLUMAB AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA [NCT# 03886311]

(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA

(P 135) PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL

(P 136) PRELIMINARY EFFICACY AND SAFETY OF FAMITINIB PLUS SHR-1701 IN ADVANCED SARCOMA: A SINGLE-CENTER, PHASE 2 TRIAL

(P 137) SAINT: FIVE YEAR RESULTS OF A PHASE 2 TRIAL USING IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) FOR PREVIOUSLY UNTREATED ADVANCED SOFT TISSUE SARCOMA [NCT03138161]

(P 138) SUSTAINED REMISSION/DISEASE CONTROL USING AUTOLOGOUS ENHANCED NATURAL KILLER CELLS PLUS AN IMMUNE CHECKPOINT INHIBITOR AS TREATMENT FOR RARE CHEMOTHERAPY-RESISTANT ADVANCED SOFT TISSUE SARCOMAS

(P 139) T-CELL PROFILING IN HIGH GRADE SARCOMAS

(P 140) TRABECTEDIN ENHANCES ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY BY REDUCING BARRIERS TO VIRUS SPREAD AND IMMUNE EFFECTOR FUNCTION IN PRECLINICAL BONE SARCOMA MODELS

(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.

(P 142) USE OF SMALL MOLECULE STIMULATE OF TYPE-1 INTERFERON GENES (STING) AGONIST IMMUNOTHERAPY FOR CANINE SARCOMA: A CROSS-SPECIES ANALYSIS